ArticleERJ open research2026
Concavity of the maximal expiratory flow-volume curve, and incidence of COPD and respiratory symptoms: a population-based cohort study.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Morphological Analysis of the Flow-Volume Curve for Identifying Fixed Airflow Obstruction: A Scoping Review.Advances in respiratory medicine · 2026Article
- An index of maximal expiratory flow-volume curve with different features related to central and peripheral concavity.ERJ open research · 2026Article
- Reply: An index of maximal expiratory flow-volume curve with different features related to central and peripheral concavity.ERJ open research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concavity of the maximal expiratory flow-volume curve is widely regarded as an early indicator of obstructive airways disease. However, its discriminatory accuracy for respiratory outcomes has remained poorly defined. We aimed to examine the discriminatory accuracy of concavity of the maximal expiratory flow-volume curve Methods: Spirometry was performed on a subset of the Tasmanian Longitudinal Health Study cohort at age 45 years, and incidence of COPD and respiratory symptoms were prospectively monitored over the next 8 years (n=852). Central and peripheral concavity were assessed using a published algorithm based on post-BD forced expiratory flow at 50% of the FVC (FEF Results: Among participants without COPD at age 45 years, central and peripheral concavity were greater in those who developed COPD by age 53 years than in those who did not (mean difference: +20%, 95% CI 12-28, and +15%, 95% CI 7-23, respectively). Central concavity above the optimal threshold (27%) had a sensitivity of 70% and specificity of 79% for COPD incidence, while peripheral concavity above the optimal threshold (47%) had a sensitivity of 79% and specificity of 50%. Excess central and peripheral concavity were associated with an increased odds of developing wheeze and exertional dyspnoea over the 8-year follow-up. Post-BD FEV Conclusion: Concavity indices were more useful for assessing future risk of respiratory symptoms but had lower discriminatory accuracy for COPD incidence compared to post-BD FEV
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.